JHN Journal (Download the full PDF of this issue) by Rosenwasser MD, Robert H.
JHN Journal
Volume 4 | Issue 2 Article 1
Winter 12-1-2008
JHN Journal (Download the full PDF of this issue)
Robert H. Rosenwasser MD
Thomas Jefferson University, Robert.rosenwasser@jefferson.edu
Follow this and additional works at: http://jdc.jefferson.edu/jhnj
Part of the Neurology Commons
Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
JHN Journal by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Rosenwasser MD, Robert H. (2008) "JHN Journal (Download the full PDF of this issue)," JHN Journal: Vol. 4: Iss. 2, Article 1.
Available at: http://jdc.jefferson.edu/jhnj/vol4/iss2/1
1Rosenwasser MD: JHN
Published by Jefferson Digital Commons, 2009
© 2008 Thomas Jefferson University, All Rights Reserved. ISSN 1558-8726 www.Jefferson.edu/Neurosurgery
General Information
Correspondence, inquiries, or comments may be submitted to the Editor, JHN Journal, 909 Walnut Street, 3rd Floor, Philadelphia, PA 19107 or email at JHNjournal@jefferson.edu 
Chairman/Editor-in-Chief
Robert H. Rosenwasser, MD, FACS, FAHA
Editor 
Mitchell G. Maltenfort, PhD
Assistant
Janice Longo
Cover
Denise Cotter
Graphic Design
JeffGraphics 
Denise Hansen
VOL 4, ISSUE 2  l  DEC 2008
2
JHN Journal, Vol. 4 [2009], Iss. 2, Art. 1
http://jdc.jefferson.edu/jhnj/vol4/iss2/1
Table of Contents 
Articles
Minimally Invasive Surgery for Skull Base Tumors
James J. Evans, MD and Marc R. Rosen, MD ....................................................................... 2
Clinical Guidelines Written by Residents
David W. Andrews, MD ...................................................................................................................... 4
Spinal Cord Stimulators: an Introduction
Steven Falowski, MD ..................................................................................................................11
Surgeon Opinions on Use of Epidural Steroids in Treatment of 
Lumbar Disk Disease: Results of an Online Survey
John K. Ratliff MD, Mitchell Maltenfort PhD, Bryan Lebude .....................................................13
Case Reports
Intramedullary Cervical Spinal Cord Hemangioblastoma with an 
Evaluation of von Hippel-Lindau Disease
Steven Falowski, MD, Ashwini Sharan, MD, James S. Harrop, MD, John K. Ratliff, MD ...... 16
Cervical Intramedullary Ganglioma
Harminder Singh, MD, Ashwini Sharan, MD, John K. Ratliff, MD ......................................... 18
Intramedullary Spinal Cord Metastases and Radiation Therapy
Daniel Ikeda, James S. Harrop, MD ..................................................................................... 21
 Departmental Information
Contact Information ....................................................................................................... 23
Research Studies
 Published Articles ........................................................................................................... 24
Ongoing Research Studies ........................................................................................... 26 
JHN JOURNAL 
3
Rosenwasser MD: JHN
Published by Jefferson Digital Commons, 2009
 JHN JOURNAL 
Minimally Invasive Surgery     
for Skull Base Tumors
James J. Evans, MD1 and Marc R. Rosen, MD2
1Department of Neurological Surgery and 2Department of Otolaryngology-Head and Neck 
Surgery Thomas Jefferson University, Philadelphia, Pennsylvania
The Jefferson Center for Minimally Invasive Cranial Base Surgery and Endoscopic Neurosurgery 
reflects three of the current evolutions in neurological surgery.  The first of these is reflected in the 
name of the Center itself.  Surgical Procedures, Minimally Invasive, a Medline Subject Heading since 
1998, is defined as: 
Procedures that avoid use of open invasive surgery in favor of closed or local surgery. These 
generally involve use of laparoscopic devices and remote-control manipulation of instruments 
with indirect observation of the surgical field through an endoscope or similar device. With 
the reduced trauma associated with minimally invasive surgery, long hospital stays may be 
reduced with increased rates of short stay or day surgery.
Traditionally, cranial base tumors have been removed by making craniotomies or cranial base 
ostomies, and possibly by removing facial bones.  To access these areas, surgeons usually need to 
make potentially disfiguring incisions in the face and scalp.  Sometimes the morbidity from the 
“open” cranial base approach alone could be significant, even with an uneventful removal of the 
tumor.  
At the Center, the endoscopic approaches are usually through the nose or nasal passages (Figure 1), 
however transoral endoscopic approaches to the cranial base and cervical spine are also performed. 
Because morbidity from the minimally invasive endoscopic approaches is so low, it becomes possible 
to treat patients with tumors that were previously considered non-resectable or as having too poor a 
prognosis for more invasive surgery.  Even partial resection of such tumors can relieve pain, preserve 
function, and permit earlier adjuvant radiation and chemotherapy.  
James Evans, MD and Marc Rosen, MD, both faculty at Jefferson Medical College of  Thomas Jefferson 
University (Evans in Neurological Surgery, Rosen in Otolaryngology-Head and Neck Surgery), are 
the Center’s co-directors.  Their collaboration represents another evolution, the increasing interaction 
between medical and surgical disciplines (Figure 2).  Both specialties bring unique instruments, 
surgical techniques, and clinical experience that have been merged to exponentially increase our 
understanding and management of cranial base tumors and disorders.  Treatment of these patients 
in the Center also draws upon knowledge and resources from many other departments including 
Radiology, Oncology, and Ophthalmology.  
The third evolution is in the tracking of patient outcomes.  Through the Center, we have developed a 
specialized database for tracking patient demographics, neurological examinations, ENT parameters, 
endocrine function, ophthalmologic evaluations, tumor control, morbidity, and outcomes.  Data 
collection is essential for confirmation of treatment efficacy and safety. Continual re-evaluation of 
the treatment process and results can be critical when developing and validating new endoscopic 
techniques.  Also, the “Pay for Performance” movement is a recent addition to the reasons why 
clinical organizations need to collect and store data that can be searched and cross-referenced.  Data 
at our Center is stored and retrieved using a Microsoft Access database application designed in-house 
(Figures 3 and 4).  With five years of accumulated data, the Center is now getting a clear view of what 
it has achieved and what the next goals should be.  
Many of the Center’s patients present with pituitary tumors.  Pituitary adenomas represent one of the 
most common brain tumors and were the first type of tumor where endonasal endoscopic techniques 
were used.  Sixty percent of the patients seen by the Center for such tumors present with visual 
deterioration.  A recent study published by members of our Center has shown that ophthalmologic 
studies such as optical coherence tomography 
not only document the extent of presenting 
visual loss, but may be used as a predictor of 
visual improvement with resection of the tumor 
and decompression of the optic chiasm.
Another area of interest in our Center is the 
extension of cranial base approaches to include 
tumors involving the cervical spine.  Figure 1 
shows an endoscopic transnasal view of the 
posterior pharyngeal wall and accompanying 
intraoperative navigation images.  We have 
recently completed a morphometric study on 
over 100 patients to determine the factors that 
affect the extent of cervical spine access via an 
endonasal surgical approach.  These findings 
have led to the development of new techniques 
and instruments for endonasal cervical spine 
surgery.
Endoscopic transnasal procedures continue to 
benefit from technological developments such 
as real-time intraoperative imaging (MRI, CT), 
dedicated endoscopic surgical suites, and the 
development of new materials and techniques 
for cranial base repair.  We are also exploring 
the adaptation of surgical robotics systems to 
augment the precise and delicate nature of these 
endonasal surgical procedures.    
 
Table 1.  Advantages of Endoscopic 
Surgery over “Open” Surgery
Better preservation of function and 
appearance
Lower morbidity rates
Shorter hospital stays 
Greater resections of tumors 
Facilitates re-operations 
Permits earlier post-operative radiation and 
chemotherapy 
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Tumors
Figure 1
Endonasal navigation during surgery
Figure 2
Multidisciplinary surgical team
Figure 3
Interface page for 
database – image 
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coded by type, and 
selecting image 
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Clinical Guidelines Written by Residents
David W. Andrews, MD
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania 
Anticonvulsant use in brain tumor patients
Hugh Moulding, MD
More than 200,000 patients are diagnosed with primary or metastatic brain tumors each year in 
the United States. Of these patients, 20% to 40% will develop seizures at presentation, and another 
20% to 40% will require treatment for seizures during their illness. Although the use of antiepileptic 
drugs (AEDs) in patients who have had seizures seems reasonable, the issue of prophylactic AED 
use for patients who have not had a seizure is an intensely debated subject.
At TJUH, we see the wide variety of practices in prophylactic use of anticonvulsants.  Some physi-
cians will use anticonvulsants and follow therapeutic levels, others will use a starting dose of AED 
and not follow levels, and still others will not use AED at all.  The reason for the discrepancy is 
most likely multifactorial.  There is little evidence to the benefit of AEDs in patients who have not 
had seizures when considering the side effect profile of AEDs.  However, give the litigious climate 
of Philadelphia, many neurosurgeons are reluctant to leave a patient with an intracerebral lesion 
without antiepileptic coverage.  Additionally, many neurosurgeons are creatures of habit, trained 
to practice a certain way, and have done so for many years during which “it has worked or them so 
far.”  A set of guidelines based on a literature search, where level I evidence is cited where possible, 
would help physicians to be more comfortable about changing their practice.
“Variation” is an innocent word that that can represent many levels of frustration to the clinician.  Variation among patients is the least of these; 
the physician expects patients and their individual problems to be as diverse as the human race itself. Variation within a practice should be due 
to matching the specific needs of the specific patient. Other variations can mean trouble if they represent differences in understanding of the 
problem among clinicians and other allied health practitioners. These differences could be between institutions or even between shifts within 
one institution. 
The Tufts Health Care Institute (THCI) is a non-profit organization which provides educational tools for medical and surgical residents across 
the US. One of these tools teaches clinical practice guidelines, defined by the Institute of Medicine as “systematically developed statements to 
assist practitioner and patient decisions about appropriate health care for specific clinical circumstances.”1.  One of the authors of the Clinical 
Guidelines module is David B. Nash, Professor of Health Policy here at Thomas Jefferson University.
The Jefferson Department of Neurological Surgery has been participating in the THCI program for the past few years, mentored by Dr. David W. 
Andrews of the department. Because surgery and medicine have different emphases, Dr. Andrews has found that some of the THCI modules are 
more appropriate than others for the neurosurgical residents, and that the Clinical Guidelines module in particular has generated both enthusiasm 
and good results. A selection of the TJU neurosurgical resident-generated guidelines are presented here. These guidelines have not officially been 
adopted by the department or by any institution that we know of, but show how clinical problems can be identified and solved.
References
(Institute of Medicine, 1990, p. 38)  Institute of Medicine. Field MJ, Lohr KN (eds.) Clinical Practice Guidelines: Directions for a New Program, page 38. Committee to Advise the Public Health 
Service on 
Acknowledgement
All graphics used are from commons.wikipedia.org under open licenses. The specific license of each graphic (GNU, Creative Commons) is available by looking up its 
URL.   
1.
http://commons.wikimedia.org/wiki/Image:Drug_
ampoule_JPN.jpg
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Since 2000, there have been practive guidelines 
in place approved by the American Academy of 
Neurology (see Ref 3) based on peer reviewed 
publications with level I evidence. Despite these 
practice parameters a recent survey reported 
that 81% of neurosurgeons and 53% of neurol-
ogists prescribed antiepileptic drugs (AEDs) 
prophylactically.  
For the 20-40% of patients diagnosed with a 
brain tumor who have experienced a seizure, 
prophylactic use of AEDs is universally accepted. 
Seventy percent of brain tumor patients 
presenting with seizures will suffer recurrent 
seizures regardless of tumor type. However, 
patients that have not had a seizure still remain 
at risk and 20-45% will develop seizures.  Some 
factors that have been shown to increase the 
likelihood of developing seizures are: 
1.  Tumor location, most likely in frontal, 
parietal or temporal lobes, especially 
parasagital meningiomas (74% seizure 
prevalence). 
2.  Number of tumors: increased number of 
tumors correlates to higher seizure risk. 
3. Tumor histopathology: Slow growing 
tumors are at increased risk.  
4. Age: younger patients more likely to seize.  
One factor that is conspicuously absent from 
the list above is AED use. Of the twelve studies 
of Level I & II data that examined this question, 
only one reported a significant difference in 
seizure frequency and this favored the non-
AED group having a lower seizure risk. A 
meta-analysis performed on the four Level I 
studies showed an Odds Ratio of 1.09 with no 
statistical significance (p=0.9). Furthermore 
AED use is not benign; 23.8% of these patients 
experience side effects that warranted change 
or discontinuation of the AED. These side 
effects included rash (14%), nausea and 
vomiting (5%), encephalopathy (5%), and 
myelosuppression (3%). 
References
Sperling MR, Ko J:  Seizures and brain tumors.  Seminars in 
Oncology.  33(3):333-41, 2006.
Stevens GHJ:  Antiepileptic therapy in patients with central 
nervous system malignancies.  Current Neurology and 
Neuroscience Reports.  6(4):311-8, 2006.
Glantz MJ, Cole BF, Forsyth PA, et al.:  Practice parameter: 
anticonvulsant prophylaxis in patients with newly diagnosed 
brain tumors: report of the quality standards subcommittee 
of the American Academy of Neurology.  Neurology.  
54:1886-93, 2000.
1.
2.
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Cervical spondylotic myelopathy
Amgad Hanna, MD
Cervical spondylotic myelopathy is a common 
cause of major morbidity in middle-aged and 
elderly people. Various functional classifica-
tions are used to evaluate patients with cervical 
spondylosis. They are based on pure clinical 
data, and are used as a method of evaluation of 
the patient’s progress during the course of the 
disease. None of these classifications defines 
criteria for the indication for surgery.
Patients with cervical myelopathy may be 
managed either conservatively or surgically. 
Conservative management includes medica-
tions (e..g, non-steroidal anti-inflammatories 
or corticosteroids), cervical orthotics, physical 
therapy, or injections. Surgery includes ante-
rior and/or posterior decompression and/or 
fusion.
There remains considerable uncertainty 
regarding the decision to operate and the 
timing for surgery. This is left to the surgeon’s 
discretion in most of the cases. Most surgeons 
would agree that patients with mild myelopa-
thy should be managed conservatively and 
patients with severe myelopathy should be 
managed surgically. There is a large gray zone 
of moderate myelopathy where surgeons may 
decide about surgery or conservative manage-
ment. The definition of mild, moderate, or 
severe myelopathy is vague in literature. 
The timing of surgery is also controversial 
in literature. Advocates of early surgery try 
to stop disease progression, prevent further 
clinical deterioration of the patients, and pre-
vent the risk of acute deterioration with neck 
injuries (central cord syndrome). Advocates 
of late surgery try to delay the potential 
complications of surgery like adjacent level 
disease, spinal cord injury, cerebrospinal fluid 
leak, infection, bleeding, and possible clinical 
deterioration.
We attempt to address the literature 
controversies regarding this topic, the severity 
of myelopathy, and the indications for surgery.
Online search for resources
National guideline clearinghouse. We 
searched for “cervical myelopathy”. No 
guidelines were found for the management 
of cervical myelopathy. Related guidelines 
were found for cervical radiculopathy: 
Review criteria for cervical surgery for 
entrapment of a single nerve root. Olympia 
(WA): Washington State Department of 
Labor and Industries; 2004 June. 1p. The 
article states that “Cases of myelopathy 
should be referred for physician review”.
The Cochrane Library. We searched for “cer-
vical myelopathy”. One article was found: 
Cochrane review on the role of surgery in 
cervical spondylotic radiculomyelopathy. 
Fouyas I, Statham P, Sandercock P. Spine 
2002; 27 (7): 736-47
Medline search: www.ncbi.nlm.nih.gov. 
We searched for “management of cervical 
myelopathy”; 104 articles were found
Summary of findings
There are no current guidelines for the man-
agement of cervical spondylotic myelopathy. 
Several articles (1,2) discussed the prognostic 
factors and presented surgical outcomes. These 
articles presented conflicting results as far as 
the prognostic significance of signal changes 
on MRI, age, and duration of symptoms.
Other studies discussed the indications and 
outcomes of different surgical approaches. 
Again, conflicting results were found. Fouyas 
et al. found no significant longterm differences 
between surgery and conservative manage-
ment3. Houten, Kim, Medow, Komotar, and 
Sekhon showed good results with surgical 
decompression 2, 4-7. However, there was no 
comparison to conservative management.
Guidelines
The two articles selected are references 2 and 3. 
Reference : Houten, Cooper (00)
Full reference: Laminectomy and posterior cer-
vical plating for multilevel cervical spondylotic 
myelopathy and ossification of the posterior 
longitudinal ligament: effects on cervical align-
ment, spinal cord compression, and neurologi-
cal outcome. Houten J, Cooper P. Neurosurgery 
2003; 52 (5): 1081-8
1.
2.
3.
Resident Education
http://commons.wikimedia.org/wiki/Image:The_
Thinker_wideshot.jpg
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Results 
Multilevel cervical laminectomy and 
fusion for cervical spondylotic myelopa-
thy provide minimal morbidity, excel-
lent decompression, immediate stability, 
prevent kyphosis, and precludes further 
spondylosis.
Strengths
Combined clinical and radiological crite-
ria for outcome after surgery.
Thirty months follow up.
Weaknesses
Retrospective study. 
Small number of patients (38).
No comparison group with conservative 
management. 
No consideration for bony fusion vs 
pseudoarthrosis.
Reference : Fouyas, Statham, Sandercock 
(00)
Full reference: Cochrane review on the role of 
surgery in cervical spondylotic radiculomy-
elopathy. Fouyas I, Statham P, Sandercock P. 
Spine 2002; 27 (7): 736-47
Results
No significant difference in long term out-
come between surgical and conservative 
management for cervical myelopathy.
Strengths
Prospective randomized trials.
Weaknesses
Patients represented in the studies had 
mainly mild functional deficit. They do 
not represent the population that usually 
benefits from surgery, who have moder-
ate to severe myelopathy.
-
-
-
-
-
-
-
-
-
-
Final Guideline   
This guideline targets mainly neurosurgeons 
and orthopedic spine surgeons who need to 
decide for their patients whether to proceed 
with surgical or conservative management. It 
also targets primary care physicians to guide 
them as to which patients need to be referred 
for surgery. 
Evaluation of the severity of myelopathy:
The following scoring system is proposed to 
evaluate the severity of cervical myelopathy:
Comments
This is the first grading system to include 
both clinical and radiological data.
Mild to moderate symptoms: mild pain or 
numbness. Severe symptoms: severe pain 
or numbness, loss of dexterity, difficulty in 
walking.
Mild to moderate signs: hyper-reflexia, 
Hoffman’s or Babinski’s signs, mild weak-
ness. Severe signs: significant weakness, 
spasticity.
Moderate stenosis: Mid-sagittal diameter: 
10-12 mm. Severe stenosis: Mid-sagittal 
diameter: < 10 mm.
The recommendations are based on the best 
available literature.
This is just a guideline. Cases need to be 
managed individually, based on the whole 
clinical scenario, progression of the disease, 
and co-morbidities.
References
Effect of intramedullary signal changes on the surgical 
outcome of patients with cervical spondylotic myelopathy. 
Suri et al. Spine J 2003; 3 (1): 33-45
Laminectomy and posterior cervical plating for multilevel 
cervical spondylotic myelopathy and ossification of the 
posterior longitudinal ligament: effects on cervical align-
ment, spinal cord compression, and neurological outcome. 
Houten J, Cooper P. Neurosurgery 2003; 52 (5): 1081-8
Cochrane review on the role of surgery in cervical spondy-
lotic radiculomyelopathy. Fouyas I, Statham P, Sandercock 
P. Spine 2002; 27 (7): 736-47
•
•
•
•
•
•
1.
2.
3.
Indications for circumferential surgery for cervical spondy-
lotic myelopathy. Kim P, Alexander J. Spine J 2006; 6 Suppl: 
S 299-307
Surgical management of cervical myelopathy: indications 
and techniques for surgical corpectomy. Medow J, Trost G, 
Sandin J. Spine J 2006; 6 Suppl: S 233-41
Surgical management of cervical myelopathy: indications 
and techniques for laminectomy and fusion. Komotar R, 
Morcco J, Kaiser M. Spine J 2006; 6 Suppl: S 252-67
Posterior cervical decompression and fusion for circumfer-
ential spondylotic cervical stenosis: review of 50 consecutive 
cases. Sekhon L. J Clin Neurosci 2006; 13 (1): 23-30
Does the treatment of carotid 
dissection require anticoagulation 
with coumadin or is antiplatelet 
therapy equally efficacious?
Aditya Pandey, MD
Vessel dissection represents injury to the wall 
of the vessel either from the luminal side or 
adventitial (outside) side.  Extracranial carotid 
and vertebral artery dissections represent the 
second leading cause of stroke in young adults. 
Its incidence is 2-3 persons/ 100,000/ year. 
The mechanism of developing stroke within 
this patient population is from clot formation 
at the site of the injury to the vessel.  The 
causes of carotid dissection are numerous, but 
it most commonly occurs due to a traumatic 
injury in an individual who has weakened 
vessels. To prevent such an event, patients are 
started on blood thinners: either antiplatelet 
(aspirin) or coumadin.
Depending on physician and surgeon prefer-
ence, different anticoagulation therapy can be 
used for the same type of patient with carotid 
4.
5.
6.
7.
Table 1.  Score System
No Symptoms 0 Mild to Moderate Symptoms 1  Severe Symptoms  2
No Signs 0 Mild to Moderate Signs 1 Severe Signs  2
No stenosis 0 Moderate Stenosis 1  Severe Stenosis  2
No signal changes 0   Signal Changes on MRI 2  
on MRI
Total score 1-3:  Conservative management.  Total score 4-8: Surgery.
http://commons.wikimedia.org/wiki/Image:Blut-EDTA.jpg
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Resident Education
dissection. Those who use coumadin do so 
since they have had success in treating carotid 
dissection patients without stroke formation. 
The same is true of physicians utilizing anti-
platelet therapy. The use of coumadin not only 
requires that patients have frequent blood tests 
to show level of blood thinning but also that the 
bleeding risks associated with it are higher. The 
goal of this analysis is to present the evidence 
for using coumadin versus aspirin in the treat-
ment of carotid dissection. 
Benefits of Full Anticoagulation
anticoagulation leads to the prevention of 
stroke from the formation of clots at the site 
of the vessel injury
Complications of Full Anticoagulation
anticoagulation could lead to further bleed-
ing into the brain
Specifics of Search
Search of National  Clearinghouse 
Guidelines revealed one review but no 
specific guidelines
Search of the Cochrane Database did not 
reveal any position statements on the 
subject
The following key term searches on Pub-
med led to numerous articles on the subject 
of treating carotid dissection with antico-
agulation:
“Extracranial carotid dissection”
“Treatment of extracranial carotid dis-
section”
“Anticoagulation for extracranial carotid 
dissection”
Results
Antithrombotic drugs for carotid artery dis-
section.  Cochrane Database Syst Rev. 2000; 
(4): CD 000255
Strengths
comprehensive review of case controlled 
studies and case series
applies to carotid dissection patients who 
had undergone either anticoagulation 
with coumadin or antiplatelet therapy
Limitations
no randomized control trials included in 
this study (No RCT have been performed 
addressing this issue)
Summary
26 eligible studies were reviewed (327 
patients)
•
•
•
•
•
-
-
-
1.
-
-
-
-
No statistically significant difference in 
outcome (mortality/disability) between 
patients on antiplatelet therapy versus 
those on anticoagulation (coumadin)
No difference in the occurrence of intra-
cerebral hemorrhage between the two 
groups (0% for antiplatelet group and 
0.5% for anticoagulation group)
Conclusion
no statistically significant difference in 
outcome or complication when com-
paring the anticoagulation versus the 
antiplatelet group of patients
Cervical Arterial Dissection: time for a 
therapeutic trial? Stroke. 2003 Dec; 34 (12): 
2856 – 60
Strengths
prospective enrolled patients with carotid 
and vertebral dissections
large number of patients (n=116)
comparison of aspirin vs. anticoagulation
Weaknesses
not a randomized control trial
N might not be large enough to a small 
statistically significant difference
Summary
Canadian Stroke Consortium prospec-
tively enrolled patients with extra-cranial 
dissections and followed patients for 
one year. The endpoints being evalu-
ated included: TIA, Stroke, or Death. 
105 patients had complete follow up. In 
patients treated with anticoagulation the 
event rate was 8.3% versus those treated 
with aspirin where the event rate was 
12.4%. While there was an absolute dif-
ference of 4.1%, this difference was not 
statistically significant.
Conclusion
There were no statistically significant differ-
ences between the outcome rates of patients on 
ASA versus those on anticoagulation.
Dissection of Cervical Arteries: Long-term 
follow-up study of 130 consecutive cases. 
Cerebrovasc Dis. 2006; 22 (2-3): 150-4
Strengths
Prospective Study
N=130 cases
Comparison of ASA vs. anticoagulation
Weaknesses
not a randomized control trial
F/U only 6 months
-
-
-
2.
-
-
-
-
-
-
1.
-
-
-
-
-
Summary
130 patients with angiographically 
proven cervical arterial dissection were 
followed for the events of stroke and 
death. There was no significant differ-
ences in outcome were found when 
comparing patients on aspirin versus 
the patients on anticoagulation.
Conclusion
In patients with proven carotid dissections, 
there is no difference in outcome between 
patients treated with ASA vs. those treated with 
anticoagulation.
Outcome of extracranial cervicocephalic 
arterial dissections: A follow-up study. 
Neurol Res. 2002 Jun; 24 (4): 395-8
Strengths
comparison of ASA vs. anticoagulation
long term f/u (nearly 10 years)
Weaknesses
not a randomized control trial
small patient population (n=27)
Summary
27 patients with extracrainal CAD who 
were treated and followed by the stroke 
service.  Outcome was assessed using the 
modified Rankin Score and recurrent 
stroke and TIAs were also recorded.  The 
outcome was favorable with either anti-
platelet or anticoagulation.
Conclusion
Either antiplatelets or anticoagulation are 
equally effective in preventing strokes after 
carotid dissection,
Final Guideline
In individuals with a proven extracranial 
carotid dissection, aspirin therapy should be 
initiated instead of coumadin. The current 
literature on the subject shows no statistically 
significant difference in outcome of individuals 
treated with aspirin versus those treated with 
coumadin in the setting of carotid dissection. 
While the risks with coumadin are not higher, 
it still requires evaluation of the INR for accu-
rate dosing. Such is not the requirement of 
antiplatelet therapy. In addition other medica-
tions (cimetidine) can affect the metabolism of 
coumadin thus leading to inappropriate levels 
of anticoagulation. Thus antiplatelet therapy is 
an effective method of preventing strokes in 
individuals with carotid dissection. 
-
1.
-
-
-
-
-
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Would a standardized protocol for the 
inter-hospital transport of critically ill 
patients alter outcomes? 
Jack Klem, MD 
The rapid evolution of healthcare technology 
has created a disparity among hospitals and 
thus led to the establishment of highly special-
ized quarternary institutions, termed “Centers 
of Excellence.” This has created a need for the 
systematic triage and transport of certain criti-
cally ill patients that would not receive adequate 
care at a community hospital. Emergency 
Medical Services (EMS) has made the transport 
of patients a national issue due to regionaliza-
tion, specialization, and facility designation 
by payers. Despite this, there exists a paucity 
of guidelines to direct the appropriate flow of 
patients to higher levels of care. 
Diversity exists amongst transport teams 
and overall resource allocation. Interfacility 
transport is provided by a variety of levels and 
types of personnel and agencies. The medical 
condition of the patient is not always matched 
appropriately with the acuity of care provided 
by the transport team. Less severely ill patients 
are sometimes intubated and ventilated solely 
to facilitate ease and safety of transport. 
In addition, the disease process of a particular 
diagnosis is not always understood prior to 
dispatching the appropriate means of transport 
(ie, air vs. ground). For example, patients 
with suspected aneurysmal subarachnoid 
hemorrhage require the most expeditious 
mode of transportation due the high risk of re-
rupture in the acute period. Moreover, certain 
diagnoses such as cerebellar hematoma with 
deteriorating neurological function require 
immediate transfer to the operating room with 
no need for an available ICU bed. Recognition 
of these “hyperacute” scenarios are critical to 
patient outcome. 
Guidelines are necessary to standardize inter-
facility transport on at least the regional level. 
Several steps must be analyzed in order to 
establish a systems-based protocol for inter-
facility transfer. The type of transfer must be 
established (ie, hospital to hospital, rehab to 
hospital, clinic to hospital, etc.) Next, provider 
capabilities must match the patient’s current 
and potential needs in order to provide safe and 
effective care during transport. This has been 
shown to impact outcomes in the transport of 
pediatric patients. On an administrative level, 
certification of necessity for transfer is a require-
ment for reimbursement by Medicare and 
Medicaid. This is directed by federal legislation 
outlined in the Consolidated Omnibus Budget 
Reconciliation Act (COBRA) and Emergency 
Medical Treatment and Labor Act (EMTALA). 
In summary, all of these factors must be inte-
grated in order to develop a regional or even 
national plan for interfacility transport. This 
shall streamline resource allocation and poten-
tially improve outcomes
Online Search
National Guidelines Clearinghouse was 
queried for “patient, hospital transport” and 
“interhospital transport”
Google was queried for “patient transport, 
guidelines” and “hospital transport”
Study #1: Warren at al (00)
Full reference: Warren et al. Guidelines for 
the inter- and intrahospital transport of criti-
cally ill patients. Crit Care Med 32:1 (2004) 
256- 262.
Purpose 
Development of practice guidelines for 
inter- and intrahospital transport of the 
critically ill patient in order to establish 
an efficient, organized process supported 
by appropriate equipment and personnel. 
This would ultimately enhance patient 
safety.
Methods 
Synthesis of prospective clinical outcome 
studies, retrospective reviews, and anec-
dotal reports by a task force of experts 
providing consensus opinion.
Results  
A multidisciplinary team of physicians, 
nurses, respiratory therapists, hospital 
administration and the local emergency 
medical service must justify and coordi-
nate the process by conducting a needs 
assessment of the referring hospital or 
clinic, asking whether transport is likely 
1.
2.
-
-
-
to alter the management or outcome of 
the patient.  A patient must have a pre-
liminary diagnosis that can be further 
refined and ultimately treated at a center 
that offers specialized diagnostic capabil-
ity.  Receiving hospitals should then pro-
ceed with a formalized plan addressing 
the following points:
pretransport coordination and commu-
nication
transport personnel
transport equipment: 
monitoring during transport
documentation: The patient’s medi-
cal record and relevant laboratory and 
radiographic studies must be copied for 
the accepting facility. It is also suggested 
to perform a COBRA/EMTALA check-
list to ensure compliance with federal 
regulations. 
The above five points should be evalu-
ated and refined regularly by the hospital 
using a standard quality improvement 
process. Many of the specific details from 
these guidelines are incorporated in the 
final guidelines below.
Conclusions 
When services are required that exceed avail-
able resources at a particular hospital or clinic, 
a patient will be ideally transferred to a facility 
that has the necessary resources. The decision 
to transport a critically ill patient is based on 
the potential benefits (ie, higher level of tech-
nical/cognitive/procedural care) and weighed 
against the risks. Justification for transport 
must be established and several points must 
be addressed to ensure safe and efficient 
transfer.  
Strengths of study
Article provides clear, comprehensive 
guidelines discussed above for transport-
ing patient within and between hospitals. 
Not only do these guidelines comply with 
federal regulations, but they also illustrate 
the importance of having an organized, 
efficient and standardized protocol that 
can be followed by any hospital.
Details of transport such as appropriate 
equipment and personnel are described 
in order to ensure utmost safety for the 
patient being transported. Again, this is 
an effort to standardize the entire process 
in order to eliminate “system-based” 
mistakes. For example, there exists much 
variability in the acuity of care provided 
-
-
-
-
-
-
-
-
http://commons.wikimedia.org/wiki/Image:Philadelphia_Fire_
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by transport teams due to improper 
triage, insufficient equipment, and 
inexperienced personnel. To resolve this, 
this article takes the stance that patient 
transportation must be subjected to the 
same rigors as the aviation industry in 
eliminating systems errors by establishing 
a universal set of guidelines.
Weaknesses of study
This is really the first effort in the literature 
to establish a universal set of guidelines 
and, as a result, no outcome studies are 
yet available. 
This article also assumes that every hospi-
tal has the same basic resources available 
to standardize patient transport. This 
becomes an issue with the transport of 
critically ill patients where the accepting 
hospital may have to provide the appro-
priately staffed and equipped transporta-
tion team.    
Study #: Fan et al (00)
Full reference: Fan et al. Outcomes of inter-
facility critical care adult patient transport: a 
systematic review. Critical Care 10 (2006) 1-7.
Purpose 
Determine the adverse events and impor-
tant prognostic factors associated with 
interfacility transport of intubated and 
mechanically ventilated adult patients.
Methods 
A systematic review of multiple databases 
yielded 5 case-series comprising of a total 
of 245 patients. Two of the case-series 
were prospective in design.
Results 
Data was synthesized in a qualitative 
manner due to significant heterogeneity 
in study population, outcome events, and 
results. The most common indication for 
interfacility transport was a need for spe-
cialized investigations and interventions. 
Transport modalities included air (66%), 
ground (31%) and commercial aircraft 
(3%). Transport teams included a physi-
cian in 3 of the 5 studies. Death during 
transport was rare (n=1) and no other 
adverse events or significant therapeutic 
interventions were reported during 
transport. Of note, one study reported 
a 19% (28/145) incidence of respiratory 
alkalosis upon arrival.
-
-
-
-
-
-
Conclusion 
Insufficient data exists regarding the mortality, 
morbidity, and risk factors associated with the 
interfacility transport of critically ill patients. 
Further research is necessary to understand 
which patients are most at risk while being 
transported. Recognizing the types of events 
that can occur is an important step in patient 
preparation and planning.
Strengths of study
First attempt to study outcomes of inter-
hospital transport of critically ill patients 
Weaknesses of study
This is similar to a meta-analysis that 
combines different levels of evidence 
(ie, three retrospective studies plus two 
prospective studies) and attempts to draw 
meaningful conclusions. There must be 
one prospective trial that addresses the 
same patient population.
This article looks only at adverse out-
comes that occur while a patient is en 
route rather than considering the period 
just before and after transport. This under 
reports situations, for example, where 
some patients begin to deteriorate and 
are intubated immediately upon arrival.
Study #: Ligtenberg et al (00)
Full reference: Ligtenberg et al. Quality of 
interhospital transport of critically ill patients: 
a prospective audit. Critical Care 9 (2005)  
446-51.
Purpose 
Determine the adverse events and impor-
tant prognostic factors associated with 
interfacility transport.
Methods 
prospective study describing 100 con-
secutive ICU transfers, of which 65% 
were mechanically ventilated and 38% 
on vasoactive drugs. 
Results 
Data was collected on adverse events 
before, during, and after transport. 34% 
of patients incurred adverse events with 
6 deaths being reported within the first 
24-hours after arrival. This study was 
different because not all patients were 
intubated and not all were accompanied 
by a physician as was the case in Fan et 
al. (2006). 
-
-
-
-
-
-
Conclusions 
Important factors for improvement were better 
overall communication between the refer-
ring/ receiving hospital and strict adherence to 
checklists/ published protocols.
Strengths of study
Describes a single, prospective study 
involving the transfer of 100 patients into 
only one university center. This elimi-
nates the inherent flaws of a combining 
several different studies.
Information regarding adverse events 
was collected for 24-hours after arrival. 
Weaknesses of study
There was no stratification of diagnoses. 
For example, there is no discussion as 
to why each of the 34 adverse events 
occurred. For example, was this due to 
inadequate stabilization of the patient’s 
medical condition prior to transport, 
due to inadequate care provided during 
transport, or merely patient disease?
Final Guidlines for inter-hospital transport of 
critically ill patients
Diagnosis 
Patient requires emergent surgical inter-
vention that will occur immediately upon 
arrival to the accepting institution. This 
applies to diagnoses such as cerebellar 
hematoma, EDH, or SDH in the setting 
of a rapidly deteriorating patient. This 
defines the highest acuity transfer wherein 
communication between physicians, OR 
staff, and transport personnel is critical to 
transporting a patient directly to the hold-
ing area and/or operating room in order 
to save the patient’s life. Expending time 
to “make a bed” at the accepting institu-
tion will gravely impact the patient’s 
outcome and thus must be overlooked in 
order to transport the patient as rapidly as 
possible to the operating suite. 
Patient requires emergent surgical 
intervention within 24-hours of arriving 
to the accepting institution. This applies 
to diagnoses such as SAH where cerebral 
angiogram with definitive treatment is 
performed within 24-hours of arrival. 
The caveat here is that these patients may 
develop hydrocephalus which sometimes 
cannot be treated at a referring institution 
and therefore requires emergent trans-
port. Another diagnosis is cauda equina 
where a patient will require an MRI fol-
lowed by surgery within 24-hours.
-
-
-
-
-
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Patient requires urgent imaging stud-
ies that may or may not require surgery 
in the setting of a neurologically and 
medically stable patient. This applies to 
diagnoses such as cervical spine trauma 
where the patient’s neurological status 
is not changing. For example, a patient 
with facet dislocation requiring traction 
and/or reduction.
Patient requires observation in a 
neurosurgical ICU, but remains stable 
neurologically. This applies to diagnoses 
such as a basal ganglia hemorrhage.
Patient does not have an established 
diagnosis due to lack of MRI, angiogra-
phy, etc. at the referring institution but 
remains neurologically stable. 
PRE-TRANSPORT COORDINATION 
Communication is Key 
Establish continuity of care by physi-
cian-to-physician and nurse-to-nurse 
review of patient condition and current 
treatment plan. Receiving physician 
should provide advice to aid in pretrans-
port stabilization and provide advance 
medical treatment when appropriate (ie, 
Mannitol, steroids, antiepileptic in setting 
of aneurysmal SAH with hydrocephalus). 
The appropriate arrangements should 
be made at the receiving institution to 
avoid delays in definitive treatment (ie, 
operating room standby). The mode 
of transport must also be established. 
Communication is especially critical in 
the setting of the first set of diagnoses 
described above.
TRANSPORT PERSONNEL
Education = Empowerment to Intervene
A minimum of two people should accom-
pany a critically ill patient consisting of a 
critical care nurse plus a technician. In the 
case of an unstable patient, it is recom-
-
-
-
-
-
mended that a physician with training in 
airway management and ACLS be pres-
ent. When this is not possible, some 
hospitals prophylactically intubate those 
patients who have a high risk for becom-
ing unstable en route. In the setting of 
elevated ICP, the transport personnel 
must understand the diagnosis and 
means of controlling ICP during trans-
port. For example, most patients arrive 
flat and supine which is not the optimal 
position for a patient with impending 
hydrocephalus. Transport personnel 
cannot serve as technicians, but must be 
aware of the patients diagnosis in order 
to best maintain and even optimize the 
patient prior to arrival. 
TRANSPORT EQUIPMENT
Continuity of Care
The patient must be maintained using the 
same monitors and drugs (if necessary) 
as are present in the ICU. A blood pres-
sure monitor, pulse oximeter, cardiac 
monitor/ defibrillator, basic rescucitation 
drugs, and a portable mechanical ventila-
tor when indicated.  
DOCUMENTATION:
What is the Goal of Transfer? 
The patient’s medical record and 
relevant laboratory and radiographic 
studies must be copied for the accepting 
facility. It is also suggested to perform a 
COBRA/EMTALA checklist to ensure 
compliance with federal regulations. This 
includes documentation of initial medical 
evaluation and stabilization procedures, 
informed consent disclosing risks and 
benefits of transfer, and documentation 
of physician-to-physician communica-
tion with the names of each physician 
involved. Financially motivated transfers 
are illegal. 
-
-
 The above five points serve as a gen-
eral set of guidelines that should be 
evaluated and refined regularly by 
the hospital using a standard quality 
improvement process. The hospital 
transfer center should develop a check-
list for each of the five points described 
above and follow the same steps for each 
and every transfer. Attention to details 
by methodically following the same 
steps in each situation will hopefully 
minimize “systems” mistakes and thus 
not only improve efficiency, but also 
maximize safety.
12
JHN Journal, Vol. 4 [2009], Iss. 2, Art. 1
http://jdc.jefferson.edu/jhnj/vol4/iss2/1
11JHN JOURNAL 
Spinal Cord Stimulators: 
an Introduction
Steven Falowski, MD
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania 
Background
Pain can be divided into two broad categories, nociceptive pain and neuropathic pain. Nociceptive 
pain is a dull, throbbing pain which results from irritated nerves after physical tissue injury. This is 
seen commonly in cancer or after a fracture. Nociceptive pain is amenable to treatment with pain 
medications such as opioids and/or anti-inflammatories. Neuropathic pain is described as burning, 
shooting, or shocking pain. This type of pain results from nerve damage or abnormal nerve conduc-
tion such as pain exhibited with failed back syndrome, post surgical pain, neuromas, shingles, and 
complex regional pain syndrome (previously called RSD or causalgia). Neuropathic pain tends to 
be resistant to treatment with pain medications. Neurostimulation has been an effective treatment 
option for the management of chronic neuropathic pain. It is a reversible therapy which can even be 
tested before permanent implantation.
Spinal cord stimulation (SCS) is an adjustable, non-destructive, neuromodulatory procedure which 
delivers therapeutic doses of electrical current to the spinal cord or to a targeted nerve. This low-
voltage stimulation can block the transmission of pain. The enthusiasm for SCS began with the 
introduction of the gate control theory for pain control by Melzack and Wall in 1965 1.They noted 
that stimulation of large myelinated fibers of peripheral nerves resulted in paresthesias and blocked 
the activity in small nociceptive projections.  In other words, pain receptors compete with each other 
and with other sensory afferents. Appropriate stimulation of a “rival” afferent can effectively block a 
pain signal. This is why rubbing your chin after its been hit relieves the pain – the bump is still present, 
but the rubbing blocks it. The SCS system is implanted in a space surrounding the spinal cord, called 
the epidural space, where it stimulates the dorsal columns which can mask the sensation of pain by 
producing a tingling sensation. 
Patient Selection
Some of the criteria listed below can be used to determine candidates for neurostimulation:
Conservative therapies have failed to adequately help the pain. 
Further traditional surgical intervention is not indicated. 
No serious untreated drug habituation for the pain condition exists. 
Psychological evaluation and clearance for implantation have been received, sorting out 
untreated depression or anxiety, addiction, or other behavioral disorders. 
No medical issues exist that would present problems with doing the surgery. 
Indications
The most common indications include post-laminectomy syndrome or failed back surgery syndrome 
(FBSS), complex regional pain syndrome (CRPS) or reflex sympathetic dystrophy (RSD), ischemic 
limb pain, and angina. Scattered reports regarding the treatment of intractable pain due to other 
causes including visceral/abdominal pain, cervical neuritis pain, spinal cord injury pain, post-herpetic 
neuralgia, and neurogenic thoracic outlet syndrome have also appeared in the literature.  
Surgical Technique
The procedures are most commonly performed by neurosurgeons or anesthesiologists specializing 
in pain management 2-5. A lead is temporarily utilized to cover a wide area for pain control. The 
lead, or electrode, is implanted into the epidural space. The lead is attached to a power source called 
the pulse generator (or commonly known as the battery). This is then connected to an outside or 
external system which is held in place by sterile dressings. The unit is then tested for efficacy during 
a screening period, which is usually 3-10 days.
•
•
•
•
•
Figure 2
The patient received an implanted 
transverse tripole electrode in the thoracic 
spine. The new electrode has the ability 
of focusing the electrical field into the 
dorsal column to maximize the paresthesia 
into the back while avoiding painful 
stimulation of the nerves into the ribs.
Figure 1
A patient that had persistent 
neuropathic pain in his back and his 
legs despite anterior and posterior spinal 
reconstructive surgery.
Spine 
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If relief is obtained at this point, the system may 
be implanted permanently. The stimulator is 
usually placed in an area where the skin will 
not be irritated and the unit will not be press-
ing against bone. The abdomen and buttocks 
are common locations.
Benefits
Neurostimulation has been shown to have a 
50% improvement in pain relief, reduce the use 
of medications, and allow the person experience 
an improvement in their quality of life 6-7. These 
benefits are expected to increase with improve-
ments in the technology and in understanding 
of how pain signals are generated and gated in 
the nervous system. It is important to realize 
that neurostimulation is a treatment option 
along the continuum of pain control.
Potential Adverse Effects
Surgical risks associated with an implant include 
hematoma, infection, and possible leakage of 
cerebrospinal fluid.  Because this is a device, 
there can be malfunction of the hardware or can 
have disruption in the settings by other signals; 
for example, patients with an SCS are advised 
to turn it off before going through an anti-theft 
device in a retail store; additionally, patients 
with an SCS can not undergo a magnetic reso-
nance imaging (MRI) scan.  
Summary
Spinal cord stimulation therapy has been avail-
able and approved for over two decades.  In 
the last five years, there have been significant 
advances in the technology: smaller, recharge-
able batteries; better electrodes; and improved 
implantation techniques.  More physicians are 
adapting this therapy in their practice for pain 
management and we are effectively improving 
patients’ lives.
The treatment of chronic pain remains chal-
lenging. Experience in the technique and the 
equipment has made SCS a much more reli-
able and safe modality.  Like all the modalities 
performed for chronic pain management, 
its results are favorable. It is important to 
remember that the goal of neurostimulation is 
to reduce pain, rather than to eliminate pain. 
Very few other invasive modalities can claim 
this success rate with a few years of follow-up. 
Spinal cord stimulation has earned a well estab-
lished and firm role in contemporary chronic 
pain management.
Further information is available at the Neural 
Interfaces Program Website of the NIH, http://
www.ninds.nih.gov/funding/research/npp/
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Surgeon Opinions on Use of Epidural 
Steroids in Treatment of Lumbar Disk 
Disease: Results of an Online Survey
Introduction 
“Standard of care” can vary along regional and specialty lines; it is common to discover that a 
local “standard” can be different somewhere else. Opinions may differ between pain management 
specialists, primary care physicians, and spine surgeons with regard to use of conservative 
treatment modalities. 
Opinion within a given group of practitioners, however, should converge. Local differences 
between hospitals may exist, but conferences, professional journals, and national boards for 
certification are mechanisms that should act to maintain homogeneity within a professional 
group. It could be expected that commonly utilized treatment approaches within a well defined 
group of sub-specialists should converge.
One of the more common non-surgical options for herniated lumbar spinal discs is epidural 
steroid injections (ESIs). Patients may be referred to pain management centers for lumbar ESIs 
by their primary care physician or perhaps after consultation with a surgical specialist. We 
sought to assess the opinion of practicing spine surgeons with regard to timing and use of lumbar 
ESIs as a part of a conservative treatment approach to both lumbar disk herniations (HNP) and 
lumbar degenerative disk disease (DDD). 
The definition of “conservative therapy” is 
unclear, although use of same as a control 
arm in prospective studies of surgical efficacy 
is commonplace. We sought to assess whether 
practicing spine surgeons would agree upon 
treatment protocols in their approach to 
treatment of lumbar degenerative disease and 
lumbar disc herniations. Lack of agreement on 
use of this tool in conservative management 
of lumbar disease could imply greater 
divergence in broader use of conservative 
treatment modalities.
Methods
An online survey was announced and made 
available on www.spineuniverse.com, a portal 
site for information on therapies for spinal 
conditions. Sixty-one surgeons responded 
to the survey. Because participants were self-
selected, we must be cautious about whether the 
results can be generalized. The survey questions 
are presented in Table I. Sixty-one surgeons 
responded.
There was broad divergence in all responses. 
The only clear majority was the decision to 
consider ESIs after 6 weeks of conservative 
treatment in lumbar HNP (Figure 1). In both 
HNP and DDD, the number of ESI regimens 
administered before considering surgical alter-
natives followed the same pattern: surgeons 
were likelier to favor smaller numbers of cycles, 
and going as far as 3 or 4 regimens was unlikely 
(Figure 2). Otherwise, there was no clear pattern 
in how ESIs were used (Figures 3, 4 and 5).
Bowker’s test of symmetry was used to assess 
whether surgeons were likely to use ESIs the 
same way in HNP and DDD. Statistically 
significant differences were found in the length 
of time before ESIs were considered (Figure 1; 
p < 0.01) and the length of time before invasive 
surgical options were considered (Figure 3; p < 
0.05). These results suggest that surgeons tend 
to change treatment options earlier in HNP 
than in DDD.
Discussion
If the self-selected response sample is biased, 
we might assume that the bias would tend to 
homogenize the reported opinions. Conversely, 
a small population sample may 
John K. Ratliff MD, Mitchell Maltenfort PhD, Bryan Lebude
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania 
Table 1.  
1.  When in the treatment plan do you 
consider ESIs for patients with a lumbar 
herniated disc?
after 6 weeks of conservative care
after 6-12 weeks of conservative care
after 3-6 months of conservative care
after greater than 6 months of conservative 
care
a.
b.
c.
d.
2.  What is the average number of ESI 
treatment cycles that patients with lumbar 
herniated discs normally receive before 
considering alternate treatments?
1 treatment regimen
2 treatment regimens
3 treatment regimens
4 treatment regimens or more
a.
b.
c.
d.
3.  How long are patients with lumbar 
herniated discs treated with conservative 
care and ESIs before more invasive 
treatment options are considered?
up to 6 weeks
6-12 weeks
3-6 months
Patient directed
a.
b.
c.
d.
4.  How frequently do you consider using 
epidural steroid injections (ESIs) in 
your treatment of patients with lumbar 
herniated disc?
Frequently (>75% of the time)
Often (50-75% of the time)
Sometimes (25-50% of the time)
Rarely (<25% of the time)
a.
b.
c.
d.
5.  How many ESIs are normally considered 
in a treatment regimen for patients with 
lumbar herniated discs?
1 injection
2 injections
3 injections
a.
b.
c.
1JHN JOURNAL 
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Survey Responses
Figure 1
When in the treatment plan do you consider ESIs for patients with a lumbar 
herniated disc?
Figure 2
What is the average number of ESI treatment cycles that patients with lumbar 
herniated discs normally receive before considering alternate treatments?
Figure 3
How long are patients with lumbar herniated discs treated with conservative care 
and ESIs before more invasive treatment options are considered?
Figure 5
How many ESIs are normally considered in a treatment regimen for patients 
with lumbar herniated discs?
Figure 4
How frequently do you consider using epidural steroid injections (ESIs) in your 
treatment of patients with lumbar herniated disc?
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show more difference from the “true” mean 
than would a larger sample. With these caveats, 
we may state based upon our survey that there is 
no clear consensus on how the role of epidural 
steroids in treatment of patients with HNP or 
DDD. 
The potential consequence on patient care 
is obvious. Treatment regimens given to 
individual patients are effectively randomized 
according to which surgeon assesses their case. 
While there may be no significant difference on 
outcome between three weeks or six months of 
ESI treatment, there remains a potential real 
impact on patient well-being and on medical 
expenses incurred. 
More importantly, this variance may also 
complicate attempts to study the effectiveness 
of new interventions. If “conservative” control 
treatments vary from surgeon to surgeon, and 
presumably from location to location, studies 
using “standard conservative treatment” as 
their control arm are suspect. It is possible, 
though untestable, that these variations self-
propagate as surgeons base their choices on 
both published articles and on communication 
between colleagues. 
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Case Report: Intramedullary Cervical 
Spinal Cord Hemangioblastoma with an 
Evaluation of von Hippel-Lindau Disease
Steven Falowski MD, Ashwini Sharan MD, James S. Harrop MD, John K. Ratliff MD
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania 
History of Present Illness
MO is a 49 year old male with a history of multiple sclerosis who presents with a one year history 
of progressive numbness in his shoulders bilateral and upper back. The patient describes occasional 
sharp pains that radiate to his first three fingers on his right hand. He denies weakness, clumsiness, 
difficulty walking, or bladder/bowel dysfunction. He describes no problems with handwriting, or 
fine motor skills.
Hospital Course 
A MRI of the brain was performed early in the course of symptoms demonstrating his known mul-
tiple sclerosis lesions without any changes. With continued worsening symptoms, further workup 
included an MRI of the cervical spine which demonstrated a 1 cm homogenously enhancing intra-
medullary lesion at C2 with an associated cyst and syrinx.
Prior to surgical intervention, the patient was counseled on the risks entailed in the removal of a 
spinal cord tumor. Based on the characteristics on the MRI, a diagnosis of hemangioblastoma was 
favored and therefore the possibility of having von Hippel-Lindau (VHL) disease was discussed 
with the patient. The patient underwent an MRI of the complete neuro-axis including brain and 
spinal cord screening for any other lesions. An ultrasound of the abdomen was performed which 
demonstrated no renal lesions, liver lesions, or adrenal masses. An ophthalmologic examination 
demonstrated none of the stigmatisms associated with VHL.
Prior to surgical excision, an angiogram was performed for the potential to embolize any large vessels. 
However, no tumor blush was appreciated during the angiogram. 
The patient underwent a laminectomy from C1-3 to expose the spinal cord. Intra-operative ultra-
sound was used to isolate the borders of the nodule and define the cystic component. A dural incision 
and midline myelotomy was performed. The tumor was removed en bloc and the cyst decompressed. 
The tumor was noted to be significantly vascular. Intra- operative ultrasound was utilized to confirm 
full resection. During removal of the tumor somatosensory evoked potentials were noted to decrease 
by approximately 50% in all four extremities.
The patient worked with physical therapy and 
was discharged home on post operative day 
number four. His post operative incisional pain 
was controlled with Percocet. The patient was 
also administered Valium and Neurontin to help 
with the neck pain and parasthesias following 
the surgery. The patient’s neurological exam on 
discharge demonstrated mild numbness in the 
right upper extremity and slight weakness in 
right hand grip, with resolution of preoperative 
sensory deficits in the lower extremities. 
Motor exam was 5/5 in all other muscle 
groups. Postoperative MRI demonstrated no 
residual tumor with expected post operative 
changes. Pathology was consistent with 
hemangioblastoma. In follow up the patients 
remaining right upper extremity numbness had 
resolved and the patient was able to return to 
work 8 weeks postoperatively.
Discussion
The decision to proceed with surgery was based 
on the natural history of this tumor. It may 
continue to grow and with further expanding of 
the syrinx or cystic cavity may produce further 
neurological deterioration. It can be anticipated 
that the best time for surgery would be while the 
patient has a strong neurological status and best 
chance for recovery.
Hemangioblastoma is a vascular neoplasm 
of the central nervous system. It is the most 
common primary neoplasm in the adult cer-
ebellum, but is rarely a tumor of the spine1. 
Hemangioblastoma may occur sporadically 
or as a component of von Hippel-Lindau syn-
drome. Radiological findings such as associated 
cyst, an associated syrinx, and/or surrounding 
spinal cord reaction or edema2, 3 are helpful in 
diagnosing hemangioblastoma. Thirty-two per-
cent of patients with spinal hemangioblastoma 
have von Hippel-Lindau syndrome. Symptoms 
of spinal hemangioblastoma are similar to those 
of other spinal canal tumors and include sensory 
change, motor disturbance, and pain. Because 
the presentation of spinal hemangioblastoma is 
similar to that of other spinal canal masses, MRI 
studies can be useful in suggesting a diagnosis2.
VHL is a rare genetic condition. The disease is 
an autosomal dominant disorder carried on the 
third chromosome with near complete penetra-
tion and variable expression4. The gene behaves 
Past Medical History Hypertension, Diverticulits, Multiple Sclerosis, optic neuritis
Past Surgical History Inguinal hernia repair, Colectomy, Re-anastomosis of bowel
Social History Inguinal hernia repair, Colectomy, Re-anastomosis of bowel
Allergies NKDA
Medications Toprol, Beta Interferon
Initial Neurological Exam The patient’s exam was consistent with a decrease to light touch in  
his bilateral lower extremities and right upper extremity. Pinprick 
and proprioception were intact. Motor strength was 5/5 in all muscle  
groups. There were no difficulties with tandem gait. Reflexes were 2+ 
throughout and symmetric. The patient had showed neither 
Babinski’s nor Hoffman’s sign.
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as a typical tumor suppressor gene. The age of 
onset, as well as severity is variable. There are 
various subtypes which characterize the risks of 
developing renal call carcinoma, pheochromocy-
toma, and angiomatosis. Angiomas are the most 
common presenting signs and symptoms of this 
disease syndrome. Of note, only 20% of patients 
with VHL develop pheochromocytomas. 
Features of VHL can include hemangioblasto-
ma’s in the cerebellum and spinal cord, as well 
as angiomatosis in the retina and other organs.1 
Other features include pheochromocytoma, 
renal cell and pancreatic cysts, renal cell carci-
noma, as well as café au lait spots. Neurological 
sequeala and death arise from complications 
associated with central nervous system tumors, 
as well as cardiovascular instability secondary 
to a pheochromocytoma. Decrease in visual 
acuity and blindness may arise as well5.
Work up for suspected VHL can include genetic 
studies, as well as Vanillylmandelic acid levels 
in urine. Imaging studies can include an MRI 
of the brain and spinal cord, ultrasound and/or 
CT of the abdomen, and ophthalmic exam with 
ocular dopplers5. VHL is usually a progressive 
disease and therapy should begin as soon as the 
diagnosis is made. Surgical treatment is usually 
indicated.
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T1 axial MRI post contrast
Figure 2
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Cervical Intramedullary Ganglioma
Harminder Singh MD, Ashwini Sharan MD, John K. Ratliff MD
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania 
A 48 year male presented to the ER with severe headaches which were episodic in nature and which 
had been present for several weeks. Patient had a history of traumatic head injury (TBI) several years 
prior. Otherwise, he was in good health with no significant past medical or surgical history.
On physical exam, patient was oriented x 3 with an intact cranial nerve exam. He had significant 
upper and lower extremity spasticity with mild hand intrinsic weakness. His motor exam was oth-
erwise unremarkable. His gait was very spastic. He had sustained lower extremity clonus, upgoing 
toes, and increased tone in the upper and lower extremities. His sensation was intact to light touch, 
pinprick, proprioception and temperature. 
What imaging studies would you order?
A CT scan of the brain was initially obtained secondary to the severity of the patients’ headaches and 
past history of TBI.
The head CT revealed an old lacunar infarct in the left basal ganglia. There was no intracerebral hem-
orrhage or extra axial collection. However, in the spinal cord at the level of C1, an 8 mm hypodensity 
was noted.
This prompted an MRI of the cervicomedullary junction.  An ovoid, 1.1 x 1.0 x 1.7 cm intramedullary 
lesion was seen expanding the cervical cord at the C1-2 level. It was hyperintense on T2-weighted 
images and hypointense on T1 weighted images, and demonstrated some mild curvilinear enhance-
ment within the lesion. 
What is your differential diagnosis?  Would you perform any further imaging?
These radiographic findings were consistent with a low grade tumor such as an astrocytoma. An 
ependymoma or cord metastasis were considered less likely. 
No evidence for primary malignancy was found on imaging of the chest, abdomen and pelvis.
Imaging of the entire neural-axis did not reveal any other lesions.
A CSF flow study on MRI was also performed to look at CSF flow dynamics, and evaluate for pos-
sible CSF outflow obstruction secondary to this lesion, which might have explained the patient’s 
headaches. Unobstructed CSF flow was identified anterior and posterior to the cervicomedullary 
junction at the foramen magnum and at the level of the intramedullary lesion at C1-C2. 
How would you treat this lesion? 
Observation and close neurological follow up
Perform a lumbar puncture for CSF cytology
Radiation and/or chemotherapy
Excisional biopsy 
Excisional biopsy followed by radiation and/or chemotherapy
This is a young, otherwise healthy male who is starting to develop neurological symptoms from 
a lesion with unknown pathology. Considering the rapid progression of his symptoms over a few 
weeks, we felt that it was necessary to expediently secure him a diagnosis via direct exploration of the 
lesion. Once the diagnosis was established, treatment tailored to his particular ailment could begin. 
While operative exploration of this lesion entails risk of significant morbidity, we felt the severity of 
his clinical findings and the progression of his deficit merited operative exploration.
A.
B.
C.
D.
E.
The diagnostic yield from CSF cytology is 
low (~26%)(3), although repeated sampling 
does increase the yield significantly. CSF flow 
cytometry also increases the diagnostic yield 
over CSF cytomorphology alone. (1) Newer 
techniques  like  fluorescence in situ hybridiza-
tion (FISH)  enhance the diagnostic yield for 
Figure 1
Pre-op axial non-contrast CT head showing 
hypodensity within the spinal cord
Figure 2
Pre-op sagittal T1-weighted MRI
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the detection of malignancy on the first lumbar 
puncture in patients clinically suspected of 
having leptomeningeal metastases (LMM). (10) 
Radiographic imaging did not demonstrate any 
leptomeningeal spread in our patient.  In the 
absence of leptomeningeal spread, the chances 
of obtaining a diagnosis from CSF cytology are 
further diminished.
We decided to proceed with exploration and 
biopsy of the tumor. We planned to debulk  the 
tumor and to possibly resect the entirety of the 
tumor predicated upon the lesion’s  histopatho-
logical findings at the time of frozen section and 
intraoperative behavior.  Debulking the tumor 
would also alleviate the mass effect on the spinal 
cord, decrease tumor burden, and afford the 
patient a better chance at tumor control through 
adjuvant chemotherapy and radiation. 
How would you counsel the patient regarding 
the surgical risks?
The risks and benefits of surgery were explained 
at length. It was emphasized to the patient that 
there was a substantial risk of neurologic wors-
ening and a significant risk of paralysis second-
ary to the size of the tumor and its extremely 
sensitive location. The patient had previously 
suffered a significant head injury; hence, these 
discussions were also carried out with patient’s 
mother who acted as his guardian. While the 
patient was felt to be thoroughly consentable, 
the patient’s family was again counseled as to 
the severity of his diagnosis and the significant 
dangers of surgery.
What surgical approach would you 
use?  What intra-operative tools would 
help you in localization of this lesion?
We decided to approach this lesion through a 
posterior cervical approach. The patient was 
positioned prone using the Mayfield three-pin 
headholder. The patient’s neck was placed 
in gentle flexion to facilitate exposure of the 
occipitocervical junction. The posterior arch of 
C1, along with 50% of the top of the lamina of 
C2 was removed.  At the base of the occiput, we 
performed a limited suboccipital craniectomy 
using the Midas-Rex drill.  
The dura was opened next. Using intraopera-
tive ultrasound localization, we identified the 
patient’s large intramedullary tumor. We 
attempted to map the spinal cords’ midline 
using SSEPs; however, due to poor recordings 
and extensive lateral spread, we were unable to 
adequately map the posterior elements.  
We chose an entry point along the posterior 
elements.  The spinal cord was entered via 
bipolar and creating a sharp incision in the 
Figure 3
Pre-op sagittal T2-weighted MRI
Figure 4
Pre-op sagittal post-gadolinium MRI
Figure 5
Intraoperative ultrasound image, pre 
resection
Figure 6
Intraoperative ultrasound image, post 
resection
Figure 8
Post-operative sagittal MRI
Figure 7
Post-operative sagittal CT
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pia mater.  The cord was opened further using 
microscissors. Using blunt dissection, we gently 
reflected the pia-arachnoid. Using pial sutures, 
we gently retracted the spinal cord bilaterally. 
The patient’s intramedullary tumor was evident. 
Using blunt dissection, we gently developed 
a plane around the patient’s intramedullary 
tumor. A biopsy was obtained and sent for 
frozen section. Frozen section returned a low-
grade astrocytoma.  
We continued our resection, removing as much 
of the tumor as we felt safe. We periodically 
checked motor evoked potentials during our 
decompression. After we had completed our 
decompression, we used the ultrasound to 
confirm that no further gross elements of 
tumor were evident. There was a gliotic shell, 
which was evident around the spinal cord; 
however, based on ultrasound localization, the 
main portion of the patient’s tumor had been 
successfully extirpated.
There was some mild loss of hand intrinsic 
motor evoked potentials during the procedure; 
however, this was less than 50% loss and was 
not felt to be severe.  After hemostasis had been 
achieved, the wound was thoroughly irrigated. 
The dura was closed using #6-0 Gore-Tex 
sutures.
Postoperatively, the patient recovered well. His 
motor and sensory exam remained stable.  
Permanent section was consistent with that of 
ganglioglioma. 
Ganglioglioma was first described by Courville in 
1930 as a central nervous system neoplasm con-
taining both astrocytic and neuronal components.  
Gangliogliomas are firm grayish tumors that 
may have cystic components. On light micros-
copy, atypical dysplastic neurons, astrocytes, and 
fibrovascular stroma are observed. Infrequently, 
anaplastic degeneration occurs and involves 
the astrocytic component. Neoplastic ganglion 
cells are large and mature and reveal intense 
immunoreactivity with synaptophysin, show 
expression of the stem cell epitope CD34, and 
are often binucleated.  
Most gangliogliomas are observed in the brain. 
Temporal lobes and cerebellar hemispheres are 
the most common locations. Rarely, they may 
also develop in the spinal cord. Only 1% of 
intramedullary spinal neoplasms are histologi-
cally gangliogliomas. 
Now that diagnosis has been established, 
would you recommend any further treatment 
for this patient?
Radical surgery for intraspinal tumors can 
achieve long tumor-free survival without 
requiring adjuvant therapy.(4)  In cases of low-
grade tumor, radical excision is associated with 
minimal morbidity and an excellent long-term 
prognosis when carried out before significant 
disability occurs.(2)  Gangliogliomas are gener-
ally classified as WHO grade 1 lesions; however, 
malignant transformation can occur.
In one study, the 5-year actuarial survival 
rates for cerebral hemisphere, spinal cord, and 
brain-stem gangliogliomas were 93%, 84%, 
and 73%, respectively (p = 0.7). The event-free 
survival rate at 5 years was 95% for cerebral 
hemisphere gangliogliomas and 36% for spinal 
cord gangliogliomas (p < 0.05); for brain-stem 
gangliogliomas the event-free survival rate at 3 
years was 53% (p < 0.05). Multivariate analysis 
(Cox linear regression) revealed tumor location 
to be the only variable predictive of outcome, 
with spinal cord and brain-stem gangliogliomas 
having a 3.5- and 5-fold increased relative risk of 
recurrence, respectively, compared to cerebral 
hemisphere gangliogliomas. Histological grade 
was not predictive of outcome, although in each 
location there was a trend for higher-grade 
tumors to have a shorter time to recurrence.(6)
It is concluded that radical surgery leads to long-
term survival of patients with gangliogliomas, 
regardless of location, and adjuvant therapy 
can probably be reserved for special cases (e.g. 
tumors with a high KI 67 index). (4, 5, 7-9) 
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ated ganglion cell
22
JHN Journal, Vol. 4 [2009], Iss. 2, Art. 1
http://jdc.jefferson.edu/jhnj/vol4/iss2/1
Intramedullary Spinal Cord Metastases 
and Radiation Therapy: A Case Report
Daniel Ikeda, James S. Harrop MD
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania 
Introduction 
Intramedullary spinal cord metastases (ISCM) are a clinically rare, although devastating, complication 
of disseminated cancer. These lesions have been reported to originate from many types of solid 
tumors, although primary lung carcinoma, particularly small cell, is the most common etiology. 
These metastases, which can occur anywhere along the spinal cord, often represent the end-stage of 
the disease process with limited survival outcomes.
Patients with ISCM may develop a variety of neurological deficits with treatment goals aimed at 
palliation.  Different modalities of treatment have been found to preserve or restore ambulation and 
neurological function. The options for therapeutic intervention include surgical, chemotherapeutic, 
and radiation therapy. We describe a case of ISCM in a patient with disseminated small cell lung 
cancer with magnetic resonance imaging that illustrates a complete tumor response to radiation 
therapy
Case Report
In December of 2006, a 63 year-old male presented with extensive stage small cell lung carcinoma. 
Upon initial presentation, this patient had a very large, left pulmonary mass, mediastinal lymph-
adenopathy, multiple hepatic lesions, and several osseous lesions. Due to the extent of his disease, 
the patient was referred to medical oncology and treated with chemotherapy. A PET scan on July of 
2007 revealed radiographic resolution of his malignancy following his chemotherapy. On October 
3rd of 2007, after presenting with dizziness, it was found he had metastasis to his cerebellar vermis. 
These metastases were treated with 30 Gy of whole brain radiation therapy and his vertigo signifi-
cantly improved. A follow-up brain MRI showed a complete response to treatment with no residual 
metastases found. 
In December of 2007, the patient presented with bilateral shoulder and neck pain. The pain started 
in his right shoulder radiating to his mid neck and then to his left shoulder.  The pain had been 
intermittent, but intense, over the previous few weeks and progressed to right arm numbness. There 
was no associated muscle weakness in his upper or lower extremities bilaterally. The patient displayed 
some mild right hand intrinsic weakness; deep tendon reflexes were found to be slightly increased 
in his lower extremities versus his upper extremities.  An open MRI with and without IV contrast 
of the cervical spine was performed. A contrast enhancing mass within the cervical spinal cord was 
noted and reported as an ependymoma, due to the infrequency of intraparenchymal metastasis. To 
get better definition of the lesion, a repeat closed high-resolution MRI of the cervical, thoracic, and 
lumbar spine was performed. The cervical contrast enhancing lesion was found to be three separate 
intramedullary multifocal with measured total length of 4.5 cm (Figure 1A). There were no other 
lesions in the spinal cord. The presence of three distinct lesions in the setting of metastatic disease was 
consistent with multiple intraparenchymal metastatic disease rather than a primary intramedullary 
neoplasm (ependymoma).
The patient’s disease was in remission and 30 Gy of cervical spine radiation was administered. The 
patient reported that his symptoms of pain and numbness resolved completely with the radiation 
therapy.  
A follow-up MRI demonstrated a complete response and no evidence of the ISCM lesion (Figure 1B).  
Discussion
Although rarely reported, ISCM have been found in 0.9% to 2.1% of cancer patients by autopsy, 
suggesting that thousands of patients are afflicted yearly1. Primary lung carcinoma is the most com-
mon etiology and reported to occur in up to fifty percent of cases of ISCM2.  In one retrospective 
study, small cell lung cancer was the most com-
mon primary tumor in patients with ISCM, 
accounting for 63% of patients with primary 
lung cancer and 30% of all patients studied2. 
However, other solid tumors, including breast, 
kidney, colorectal, cervical, and ovarian cancers 
have also been reported3,4,5.  
A variety of neurological disorders charac-
terizes the presenting symptoms of ISCM 
clinically. Schiff and O’Neill reported sensory 
alteration (42.5%), pain (30%), and weakness 
(30%) as the most common initial symptoms2. 
Figure 1A
Cervical MRI, prior to 30 Gy radiotherapy
Figure 1B
Cervical MRI, post radiotherap
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The symptoms of gait unsteadiness, urinary 
incontinence, and Brown-Sequard syndrome 
have also been described2,6.  
Diagnosis of ISCM usually requires magnetic 
resonance imaging (MRI) or computerized 
tomography (CT), because plane films and 
myelography are normal in 75% and 58% of 
cases7. In addition, cerebral spinal fluid (CSF) 
analysis is often non-diagnostic with the 
most common abnormal finding of elevated 
protein in only 20% of cases8. Computerize 
tomography scanning has been found to be 
diagnostic in few patients, which is demon-
strated by increased density in the area of the 
ISCM lesions.  However, magnetic resonance 
imaging (MRI) has greater sensitivity and 
specificity7. MRI T2-weighted images show 
alterations in signal intensity based on tissue 
type and demonstrate accurate differentiation 
between normal tissue of the spinal cord and 
tumor  7.  Gadolinium is a helpful adjunct to the 
T2-weighted imaging as it reveals the enhancing 
central lesion in typical ISCM7. In a study of 30 
patients, there was only one false-negative MRI 
study, and 23 of 25 patients receiving gadolinium 
demonstrated contrast enhancement of ISCM 
lesions on MRI 2.
Treatment is generally palliative, as the median 
survival ranges from 3.9 to 5 months2,9,10.  Schiff 
and O’Neill found that patients with breast 
cancer as their primary tumor had the greatest 
median survival, which still was only 13 months. 
Patients with other primary cancers including 
lung carcinoma had a median survival of 3 
months. As with our patient, surgery is often 
contraindicated at the time of presentation, 
making the less invasive modalities of chemo-
therapy and radiation therapy the mainstays 
of treatment2,5,11. Radiation therapy has been 
shown to improve or prevent deterioration 
of neurological status. In Conill et al., they 
reported improvement of neurological symp-
toms in 83% of patients with a mean duration 
of 17.2 days. And Schiff and O’Neill reported 
preservation of ambulation in 91% of patients 
at their latest follow-up.  
Conclusions  
This case illustrates a rare complication of 
systemic small cell lung cancer. The ISCM lesion 
showed a rare complete response to radiation 
therapy, which was evidenced by magnetic 
resonance imaging and outlines the importance 
of radiation therapy in the treatment algorithm 
of these patients.
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Clinical Research Ongoing Studies
Survey on Whether Patients Will Participate in a Blood 
Transfusion Trial after Subarachnoid Hemorrhage  
Retrospective, Multi-Center Chart Review of the Wingspan™ 
Stent System with Gateway™ PTA Balloon System.  
Outcome of Patients with Ruptured Aneurysm Who 
Underwent Endovascular Coiling Procedure and Evacuation 
of Intracerebral Clot
Micrus® Cerecyte™ Registry: a Registry to Evaluate Outcomes 
at One Year Post-Embolization with the Micrus® Cerecyte™
A Randomized, Clinical Trial of Unruptured Brain 
Arteriovenous Malformations (ARUBA) 
Carotid Revascularization Endarterectomy vs. Stent Trial 
(CREST) 
Surgical Anastomosis of the Superficial Temporal Artery to 
the Middle Cerebral Artery (STA-MCA) when Added to the 
Best Medical Therapy for Carotid Occlusion (COSS)
Assessment of Intracranial Aneurysm Shape as an Indicator 
of Rupture Risk
Retrospective 5 Year Review of Follow-Up Angiogram on 
Patients with Cerebral Aneurysms Post Clipping 
Retrospective Review of Post Treatment Hemorrhage Rates of 
Patients with Arteriovenous Malformations (AVM’s)
Role of Increased CSF Production in Clinical and Radiologic 
Vasospasm 
Retrospective and Prospective Review of Peri-Operative 
Complications in Patients Undergoing Spine Surgery
Assessing Patient Perspectives of Perioperative Complications 
in Spinal Surgery
Retrospective Chart Review: the Use of Pre-Operative and 
Intra-Operative Ultrasound in the Evaluation of Peripheral 
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Safety and Treatment Characteristics of Subcutaneous 
Neurostimulation (SQS) in Patients with Chronic Pain
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Nerve Stimulator Systems. 
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Callosotomy Outcomes at TJUH
Incidence and Outcome of Patients with Spinal Fracture and 
Ankylosing Spondylitis
Magnetic Resonance Analysis of Postsurgical Temporal 
Lobectomy and Correlation to Seizure Outcome
Study of Seizure Outcomes in Patients Status Post Temporal 
Lobectomy with Secondarily Generalized Seizures Comparing 
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Use of Discarded Tissue from Frontal and Temporal 
Lobectomy
Pilot Study Comparing Various Electrode and Program 
Settings Using the EON IPG 
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Compare the Spinal Sealant System As An Adjunct to Sutured 
Dural Repair with Standard of Care Methods During Spinal 
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Changing Impedances over Time with Spinal Cord 
Stimulation Systems 
Comparison of Preoperative ISAP (Intracarotid Sodium 
Amobarbital Procedure-WADA Test) Results and Post-
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Magnetic Resonance Imaging of Spinal Cord Injury: 
Correlation with Clinical Findings and Outcome 
Use of Expandable Vs. Non-Expandable Cages in Vertebral 
Body Replacement Surgery: a Retrospective Review of 
Outcomes at Jefferson
Neurological Deterioration After Spinal Cord Injury.
Radiographic Evaluation of Intersegmental Correction 
of Cervical Kyphosis with Combined Anterior Interbody 
Grafting and Posterior Instrumented Arthrodesis
Magnetic Resonance Imaging of Cervical Spondolytic 
Myelopathy: Correlation between Findings and Outcome.
Retrospective Review of the Correlation between Increased 
T2 Weighted Signal on Cervical Spine MRI to Myelopathic 
Clinical Signs
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Jefferson University: the Failure Rate in Surgical Treatment 
with Fixation of C1-C2 Fracture
Retrospective Chart Review of TJUH Patients Who 
Obtained Epidural Injections; Looking at the Post 
Procedural Complications 
Atlanto-Occipital Dislocation (AOD) Injuries: A 
Retrospective Review of Management and Outcome 
Clinical Outcome in Closed Head Injury: a Retrospective 
Review of Patients That Received Transfusion (FFP) versus 
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A Research Study of the Surgical Techniques and Clinical 
Outcome for Interarticularis Pars Repair of the Lumbar 
Spine 
Clinical Evaluation and Incidence of C 5 Palsy after Cervical 
Spine Surgery 
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Defining the Incidence of Neurological Variability after 
Complete Thoracic ASIA A Spinal Cord Injuries
Prospective Database of Primary Spinal Neoplasms
Phase I/II Dose-Ranging Study to Evaluate the Safety, 
Tolerability, and Pharmacokinetics of BA-210 and the 
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Prospective, Multicenter, Randomize, Study Comparing the 
Use of HEALOS to Autograft in a Transforminal Lumbar 
Interbody Fusion (TLIF) Approach 
Single Blind, Randomized Evaluation of Dilute Betadine 
Solution Irrigation versus Normal Saline Irrigation in the 
Prevention of Postoperative Posterior Wound Infection in 
Posterior Instrumented Spinal Surgeries 
North American Clinical Trials Network (NACTN) for 
Treatment of Spinal Cord Injury
Flexicore Intervertebral Disc versus Circumferntial Lumbar 
Spinal Fusion for the Treatment of Discogenic Pain 
Unresponsive to Conservative Treatment Associated with 
Degenerative Disc Disease
Assessment of P-15 Bone Putty in Anterior Cervical Fusion 
with Instrumentation Investigational Plan 
Multicenter Retrospective Chart Review Reviewing the 
Safety and Efficacy of the Enterprise Stent in Patients with 
Intracranial Aneurysm 
Cordis Enterprise™ Vascular Reconstruction Device (VRD) 
and Delivery System (DS): a Humanitarian Use Device 
(HUD) 
Humanitarian Use Device: Neuroform Microdelivery Stent 
The Wingspan™ Stent System and Gateway™ PTA Balloon 
Catheter, a Humanitarian Use Device 
Stenting and Aggressive Medical Management for 
Preventing Recurrent Stroke in Intracranial Stenosis 
(SAMMPRIS)
Pilot Research Study of Coumadin versus Plavix for the 
Treatment of Phase III, Randomized, Parallel Group, 
Multi-Centre Study in Recurrent Glioblastoma Patients 
to Compare the Efficacy of Cediranib [RECENTIN™, 
AZD2171] Monotherapy and the Combination of Cediranib 
with Lomustine to the Efficacy of Lomustine Alone
Use of Fractionated Stereotactic Radiotherapy for the 
Treatment of Optic Nerve Sheath Meningiomas: a 
Retrospective Medical Record Review 
Retrospective Chart Review of Fractionated Stereotactic 
Radiotherapy for the Treatment of Residual 
Craniopharyngioma 
In Vitro Pilot Study to Determine the Capacity of Glioma 
Cells and Metastatic Intracranial Tumor Cells to Cross-
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Prospective National Study to Molecularly and Genetically 
Characterize Human Gliomas: the Glioma Molecular 
Diagnostic Initiative (GMDI)  
Prospective Glioma Patients Archival Database Including 
Parallel Clinical, Radiographic, Histopathological, and 
Unsupervised Microarray Analyses 
Exploratory Phase 2 Study Evaluating the Efficacy and Safety 
of Fibrin Sealant, Vapor Heated, Solvent/Detergent Treated 
(FS VH S/D) 500 S-APR for the Sealing of Dura Defect 
Sutures in Posterior Fossa Surgery 
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Surgical Treatment of Pituitary Tumor-Transition From 
Open to Endoscopic Approach 
Overall Experience of Pituitary Tumor Patients at Thomas 
Jefferson University 
Growth of the Cranial Base Program-Otolaryngology/
Neurosurgery Experience
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Neurosurgery 
  Grand Rounds
Fridays, 7:00 am
De Palma Auditorium
1025 Walnut Street 
College Building, Basement 
Philadelphia, PA 19107
March 19-20, 2009
Park Hyatt at the Bellevue, 
Philadelphia, PA
8th Annual  
Cerebrovascular Update 2009
Course Directors
Rodney D. Bell, MD 
Professor of Neurology  
Chief, Division of Cerebrovascular Disease 
and Neurological Critical Care
Robert H. Rosenwasser, MD, FACS 
Professor and Chairman of Neurological 
Surgery
Sponsored by
Current Concepts for
Stroke Management 
and Prevention
Overall Goals & Objectives
•  Evaluate current controversies in neurosurgery
•  Discuss routine occurrences in neurosurgical practice and evaluate  
them in terms of outcome and alternative methods of management
•  Review recent advances and current therapeutic options in the 
treatment of various neurosurgical disorders.
Jefferson Medical College of Thomas Jefferson University is accredited by the ACCME to 
provide continuing medical education for physicians.
Jefferson Medical College designates this educational activity for a maximum of 1 AMA 
PRA Category 1 Credit(s)(TM).  Physicians should only claim credit commensurate with 
the extent of their participation in the activity. 
For additional information and a schedule of speakers, please contact: 
Janice Longo  
215-503-7008 
janice.longo@jefferson.edu 
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